作为阿尔茨海默氏症疾病修饰疗法的阿维南胺-C:早期和持续的干预可以在小鼠模型中预防疾病的进展
Alen Benhur Pravin Nathan1, Areeba Aziz1, Semyeong Choi2
1Department of Biomedical Sciences, Chonnam National University Medical School, Gwangju 61469, Republic of Korea.
Cells
|June 11, 2025
概括
在小鼠模型中,早期,持续使用来自麦的天然化合物Avenanthramide-C (Avn-C) 的治疗改善了认知能力,并减少了阿尔茨海默病的病理学. 这表明Avn-C可能通过向早期神经退行过程来减缓疾病的进展.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 自然产品化学 自然产品化学
背景情况:
- 目前的阿尔茨海默氏病 (AD) 治疗方法的疗效有限,并不能阻止病变的进展.
- 正在研究天然化合物作为AD的替代干预措施.
- 之前的研究表明,在AD模型中,Avenanthramide-C (Avn-C) 有短期益处.
研究的目的:
- 为了评估持续Avenanthramide-C (Avn-C) 治疗的长期疗效.
- 在AD小鼠模型中评估Avn-C对认知功能和神经病理学的影响.
- 为了研究Avn-C治疗效果背后的分子机制.
主要方法:
- 在5xFAD和Tg2576 AD小鼠模型中,口服Avenanthramide-C (Avn-C) 三个月.
- 评估认知功能,长期强化 (LTP) 和AD病理学的分子标记.
- 对AMPK激活,酶-3,GSK3β,NF-κB信号传递和微质功能进行了研究.
主要成果:
- 持续的Avn-C治疗保留了认知功能和LTP.
- Avn-C抑制了caspase-3和GSK3β,减少了粉样蛋白和病理.
- 通过抑制NF-κB和促进微质细胞灭菌,维持了抗炎作用.
结论:
- 早期和持续的Avenanthramide-C (Avn-C) 治疗显示出减缓阿尔茨海默病进展的潜力.
- Avn-C调节多个关键的病理途径,包括粉样蛋白和蛋白积累和神经炎症.
- 通过针对阿尔茨海默氏症早期神经退行性过程,Avn-C可能会提供一种新的治疗策略.
关键词:
AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD ADD was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was这里是Avn-C.在Aβ1-42中.在 LTP LTP 中.微质细胞中的微质细胞神经炎症是一种神经炎症.的高酸化是一种超酸化.更多相关视频
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.7K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
相关概念视频
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Alzheimer's Disease: Overview
452
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452
